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The integrated US Public Health Emergency Medical 
Countermeasures Enterprise 
(PHEMCE) has made great strides in 
strategic preparedness and response 
capabilities. There have been numer-
ous advances in planning, biothreat 
countermeasure development, licensure, 
manufacturing, stockpiling and deploy-
ment. Increased biodefense surveillance 
capability has dramatically improved, 
while new tools and increased aware-
ness have fostered rapid identification of 
new potential public health pathogens. 
Unfortunately, structural delays in vac-
cine design, development, manufacture, 
clinical testing and licensure processes 
remain significant obstacles to an effec-
tive national biodefense rapid response 
capability. This is particularly true for 
the very real threat of “novel patho-
gens” such as the avian-origin influenzas 
H7N9 and H5N1, and new coronavi-
ruses such as hCoV-EMC. Conventional 
approaches to vaccine development, 
production, clinical testing and licen-
sure are incompatible with the prompt 
deployment needed for an effective 
public health response. An alternative 
approach, proposed here, is to apply 
computational vaccine design tools and 
rapid production technologies that now 
make it possible to engineer vaccines for 
novel emerging pathogen and WMD 
biowarfare agent countermeasures in 
record time. These new tools have the 
potential to significantly reduce the 
time needed to design string-of-epit-
ope vaccines for previously unknown 
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pathogens. The design process—from 
genome to gene sequence, ready to insert 
in a DNA plasmid—can now be accom-
plished in less than 24 h. While these 
vaccines are by no means “standard,” 
the need for innovation in the vaccine 
design and production process is great. 
Should such vaccines be developed, their 
60-d start-to-finish timeline would rep-
resent a 2-fold faster response than the 
current standard.
The Problem: Delayed Response 
to Emerging Infections and  
Biowarfare Attacks
According to the Commission on 
the Prevention of Weapons of Mass 
Destruction (WMD) Proliferation and 
Terrorism, medical counter-measures 
such as vaccines are critically important 
for protecting first-responders and non-
combatant (civilian) populations from 
the consequences of a bioterror attack. 
In 2008, Bob Graham (D-FL) and Jim 
Talent (R-MO), chairs of the WMD com-
mission and authors of World at Risk, 
reported that the United States was “seri-
ously lacking” in this vital capability.1 
The 2009 H1N1 influenza pandemic 
highlighted continued weaknesses in the 
national preparedness system; as a con-
sequence, Graham and Talent gave US 
bio-defense preparedness an “F” in their 
follow-up report, published in 2010.2 The 
Governmental Accounting Office (GAO) 
also reported poor inter-agency coordina-
tion on biodefense.3,4 As a result of renewed 
emphasis on biodefense, the United States 
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A Proposed Solution: Design and 
Delivery of “Vaccines on Demand”
Recent reports6 of a novel H7N9 avian 
influenza virus emerging in China have 
led to even greater scrutiny of methods 
used to respond to infectious disease pub-
lic health threats and have, in turn, pro-
vided for a “live fire” assessment of novel 
approaches. In 2009–2010, the FastVax 
group began to discuss whether existing 
tools and vaccine production platforms 
could be used to accelerate the develop-
ment of vaccines for emerging infec-
tious diseases, as illustrated in Figure 1. 
Traditional vaccine development for pre-
viously unknown pathogens takes place 
on the time scale of years. The acceler-
ated process, as proposed by our group, 
would begin with analysis of the genomic 
sequence of an emerging pathogen with 
immunoinformatics tools, followed by 
rapid design of an epitope-based vaccine 
containing the most immunogenic com-
ponents, using an integrated in silico 
approach illustrated in Figure 2. Once 
the vaccine is designed, production and 
testing would involve a four-step process 
undertaken by the FastVax consortium 
arrangement, as described below.
Several constraints affecting the pro-
posed approach bear mentioning; each of 
these is addressed in turn.
T cell epitope-based vaccines pro-
vide the minimal, essential information 
required for protective immunity T cell 
epitopes are critical mediators of cellu-
lar immunity. They are derived from a 
pathogen’s proteins via two pathways: 
(1) intracellular proteins are processed, 
and their constituent peptides are loaded 
onto major histocompatability com-
plex (MHC) class I molecules; and (2) 
exogenous proteins are processed in the 
proteolytic compartment, and their con-
stituent peptides are loaded onto MHC 
class II molecules. MHC class I and class 
II-peptide complexes are then transported 
to the surface of an APC, where they are 
exposed to interrogation by passing T cells 
(CD8+ and CD4+ T cells, respectively). 
From these different antigen processing 
and presentation pathways, two distinct 
T cell responses are generated: (1) a CD8+ 
cytotoxic T lymphocyte immune response 
that is critical for pathogen clearance, and 
distributed in different regions of the 
country that are capable of producing mil-
lions of doses of protein-based vaccines.5 
Unfortunately, despite these important 
advances in the strategic preparedness 
of US agencies for biodefense, vaccine 
design remains a significant obstacle to 
national biodefense. This is particularly 
true for the very real threat of as-yet-
undetermined pathogens for which little 
is known about their critical antigenic 
determinants and correlates of immunity, 
the key parameters used in vaccine design 
for conventional pathogens.
government has expended substantial 
resources on protecting the nation against 
a potential bioterror attack, creating spe-
cialized units for planning and prepared-
ness within the Departments of Health 
and Human Services, Defense, Homeland 
Security, Agriculture, Commerce and 
State.
Vaccine production infrastructure has 
also improved due to significant invest-
ments by the Federal government. For 
example, there are now several federally 
subsidized “Advanced Development and 
Manufacturing” production facilities 
Figure 1. two vaccine development timelines. top: traditional Vaccine Development. Bottom: 
Proposed “fastVax” timeline for development of “Vaccines on Demand.”
Figure 2. we applied the genome-to-vaccine approach to developing an epitope-based vaccine 
for avian H7n9 influenza. the design project started on April 5, 2013 and was completed 20 h later. 
for vaccine production, the genome-derived vaccine sequences would be sent by secure email to 
a plasmid DnA production facility to manufacture a DnA vaccine (Step 2); following scale-up and 
production, the vaccine would be distributed in a microneedle patch or another easy-to-distrib-
ute formulation (Step 3/4). *iCS = immunogenic consensus sequences.7
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on whether comparisons have to be per-
formed to other existing genomes and epi-
topes. Tools for carrying out the task have 
been applied to the development of vac-
cine candidates for SARS,23 2009 H1N1 
pandemic influenza,24 smallpox,25 and a 
number of other emergent and biowarfare 
agents, such as West Nile Virus, H. pylori 
and Burkholderia.7,26-28 Most recently, the 
tools were applied in May 2013 to the 
design of a vaccine for H7N9, an emerg-
ing avian-origin influenza (Fig. 2).29 The 
integration of epitope mapping into a 
step-by-step vaccine design process makes 
it possible to design vaccines in the short-
est time possible once the DNA sequence 
from the emerging infectious disease or 
biowarfare pathogen is available. Should 
errors later be found in the sequence, they 
may impact one or two epitopes. For an 
epitope-based string of beads vaccine, 
the overall impact would be minimal, 
since T cell epitopes are linear; in con-
trast, sequence variations may compro-
mise the structural integrity of a whole 
protein vaccine with negative effects on 
immunogenicity.
How many epitopes? Available evidence 
from animal studies suggests that the 
number of vaccine components (epitopes) 
required for full protection against disease 
is a small and definable subset that can be 
discovered using state-of-the-art computer 
programs such as the ones described and 
validated by EpiVax.30,31 We have pro-
posed that any FastVax vaccine would 
include a minimum of 100 broadly reac-
tive T cell epitopes in several strings, 
designed to induce multi-functional 
immune responses that are essential for 
protective immunity.32 Careful selection 
of the vaccine components, comprising 
epitopes covering most common HLA, 
can provide greater than 99% coverage of 
diverse human populations.33
Need for adjuvants? Currently, MF59 
and AS03, both oil-in-water emulsions, 
and virosome, a liposome formulation, 
are three adjuvants licensed for use in 
seasonal, pre-pandemic and pandemic 
influenza vaccines. No influenza vaccines 
containing adjuvant are FDA approved. 
T cell epitope vaccine responses may be 
enhanced through genetic immuniza-
tion.34 DNA vaccines are self-adjuvanting 
through co-encoded sequences, and thus 
Epitope-driven vaccines offer dis-
tinct advantages that should contribute 
to a reconsideration of the current vac-
cine approval process for emergency use. 
Multiple epitopes derived from more than 
one antigen can be packaged together in a 
single cassette. In this way, a broad-based 
immune response directed against mul-
tiple antigenic proteins associated with 
the pathogen can be elicited without the 
need to manufacture and administer large 
quantities of protein, much of which will 
be immunologically irrelevant or poten-
tially even reactogenic. This is likely to 
reduce formulation challenges, decrease 
cost and accelerate the development pro-
cess. The use of epitopes also helps to 
mitigate potential safety concerns stem-
ming from the use of intact recombinant 
proteins that may have undesired bio-
logical activity (e.g., enzymes, immuno-
modulators, cross-reactivity, toxins, etc.). 
For example, the NP protein of Lassa has 
been associated with immune-suppressive 
activity.20 Genome sequencing, immuno-
informatics tools and the epitope-driven 
approach now make it possible to develop 
vaccines on demand in response to emerg-
ing pathogens.
A Four-Step Process to Design 
and Deliver “Vaccines On  
Demand”
Step one: Genome-derived, epitope-
driven vaccine strategy (GD-EDV). The 
first step to making “faster vaccines” is 
to design vaccine immunogens directly 
from pathogen genomes.21 For example, 
for emerging influenza strains, the vac-
cine “payload” is constructed in silico 
using the pathogen genome sequence pro-
vided by the World Health Organization 
(WHO) or posted on GISAID (http://
platform.gisaid.org/). T cell epitope-
mapping algorithms that are integrated 
in a “vaccine design toolkit” developed by 
Martin and De Groot are applied to the 
genome sequences.22 These tools derive 
and concatenate those epitopes that have 
a high likelihood of driving an effective 
T cell response into a “string-of-beads” 
format for insertion into a vaccine deliv-
ery vehicle. The process can be performed 
in less than 24 h; the exact length of 
time required for the analysis depends 
(2) a CD4+ T helper immune response 
that is essential for robust and sustained 
antibody and cytotoxic T lymphocyte 
responses. After initial exposure to patho-
gen, memory T cells are established that 
respond more rapidly and efficiently upon 
subsequent exposure.
Because epitopes provide the essential 
information needed to trigger a protective 
immune response, epitope-based vaccines 
can be developed to recreate this response. 
Given the lengthy process that is usually 
associated with the development of killed, 
live-attenuated and whole-subunit vaccine 
approaches, an epitope-based strategy is 
one rational alternative, particularly when 
no vaccine exists and an emerging patho-
gen threatens human health on a global 
scale.
T cell epitopes do not protect against 
infection; however, they may protect 
against disease
There is published evidence demon-
strating that epitope-based vaccines can 
be protective. Vaccination with peptide 
epitopes stimulates protective immune 
responses in a range of animal mod-
els, including complete protection of 
BALB/c mice against RSV challenge,8 
partial protection of BALB/c mice against 
Plasmodium yoelii sporozoite challenge,9 
partial protection of BALB/c and CBA 
mice against encephalitis following intra-
cerebral challenge with a lethal dose of 
measles virus,10 complete protection of 
BALB/c mice from intraperitoneal HSV 
challenge,11 high degree of protection 
of BALB/c mice against infection with 
malaria or influenza A virus,12 full pro-
tection of sheep against BLV,13 and full 
protection of horses against West Nile 
Virus.14 Furthermore, experts are gener-
ally in agreement that cross-reactive T cell 
epitopes were responsible for the limited 
morbidity and mortality associated with 
pandemic H1N1 in 2009.15-17 The absence 
of T cell epitopes may be contributing to 
the rapid spread and significant mortality 
rate of H7N9 in China.18 T cell epitope-
related immune responses appear to be 
critically important for reducing morbid-
ity and mortality in human infectious 
disease.19
No “Fast Track” to vaccine-on-demand 
approval is currently possible under exist-
ing FDA regulations
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such is the case with Lassa Fever, Ebola, 
the encephaloviruses, and a number of 
other “Category A, B and C” biodefense 
pathogens. In some cases, correlates of 
protection are unknown, and either an 
antibody-focused or a T cell-driven vac-
cine may prove effective. Where antibody-
mediated immunity is critically important, 
T cell-driven vaccines still merit attention 
as potential adjuncts to more traditional 
whole-antigen (B cell-driven) approaches, 
since T cell help drives higher titer, higher 
affinity antibody responses. Especially 
in settings where challenge studies can-
not be performed in advance of use in 
humans, licensure may be possible by 
means of the “Two Animal Rule” in lieu 
of a human correlate. Rapid clinical test-
ing can be achieved using existing com-
mercial clinical research organizations and 
clinical site networks such as the Medical 
Countermeasures Clinical Studies 
Network currently envisioned by ASPR/
BARDA. Emergency use authorization 
approval can be based on achievement of 
“correlates” such as induction of broadly 
protective T cell or antibody responses, 
provided an allowed Investigational New 
Drug (IND) Application is in hand.
One problem facing T cell-driven vac-
cines that are designed to stimulate HLA-
restricted human immune responses is 
that testing for correlates of immunity as 
described in the “Two Animal Rule” may 
not demonstrate the true efficacy of the 
product. Thus alternative approaches may 
need to be considered.
The MIMIC assay, a comprehensive 
measurement of localized reactogenicity, 
could be utilized for initial safety stud-
ies and to qualify release of the actual 
vaccine intended for emergency use.38 
Additionally, in pandemic response simu-
lations, “mock up” or example vaccines (in 
a specific DNA plasmid backbone) and 
patch delivery system could be submitted 
for approval by the FDA, and this formu-
lation would be evaluated in the clinic for 
immunogenicity that recapitulates the 
influenza correlates of protective immu-
nity already defined by CBER and EMA. 
Correlates of protective immunity for cur-
rently approved influenza vaccines will not 
serve as a basis for regulatory approval of 
a DNA vaccine. The FDA would require 
correlates to be determined for a new 
The DNA vaccine delivery platform 
and rational in silico design provide for 
a strong safety profile. The DNA vac-
cine manufacturing process, particularly 
the efficient and stringent release criteria, 
allow for a highly pure and well-charac-
terized final product. Rational design 
permits in silico analysis of the vaccine 
sequence for identification of potential 
unfavorable immune responses includ-
ing regulatory sequences or cross-reactive 
immune responses. A fundamental princi-
ple of rapid biodefense vaccine production 
is that safety and speed are paramount for 
eliciting a protective immune response 
prior to the epidemic.
Delivery vehicle. The bulk vaccine 
product would then be coated onto pre-
manufactured micro-needle patches that 
provide direct delivery to the dermis, or 
would be delivered using another skin-
based method such as “scarification.” A 
number of self-applied patch delivery sys-
tems have already been developed. These 
would be optimal in bioterror and pan-
demic scenarios, because patches can be 
pre-manufactured and stored in bulk and 
do not require refrigeration for delivery or 
trained practitioners for administration.36 
Vaccination centers would not be required, 
which would minimize transmission of 
the biothreat organism between patients 
and health care providers. Alternatively, 
previously approved electroporation deliv-
ery methods37 could be used, though this 
would take more time and increase the 
need for vaccine administration personnel 
training, leading to an escalation of the 
vaccine administration expense and more 
protracted timelines.
Step three: Clinical trials. While there 
are no Phase III or FDA-approved DNA 
vaccines, there are more than 30 Phase 
II trials listed in clinicaltrials.gov. FDA 
approval of a DNA vaccine appears to be 
on the horizon, but until then, the FastVax 
DNA vaccine may encounter an additional 
FDA-associated barrier. Implementation 
of a previously untested vaccine is only 
possible after rapidly completing initial 
clinical testing to the point that “emer-
gency use authorization” can be invoked 
by the Secretary of Health and Human 
Services (HHS). In some biodefense sce-
narios, approximate correlates of protec-
tion may have been previously identified; 
many such vaccines do not incorporate 
traditional adjuvants in their final formu-
lation. A number of strategies that are cur-
rently being evaluated may improve DNA 
vaccine potency for humans, including 
use of more efficient promoters and codon 
optimization, addition of traditional or 
genetic adjuvants, electroporation and 
intradermal delivery.35
Step two: Manufacturing and produc-
tion. Reliable, reproducible methods for 
producing vaccines are currently available. 
The FastVax consortium favors DNA vac-
cines because production is scalable, the 
vaccines are stable at room temperature, 
manufacturing can be easily distributed 
to different geographic locations, and the 
production method is more rapid than 
many other vaccine manufacturing tech-
nologies. Alternative scalable and rapid 
production methods for accelerated vac-
cine production include plant-derived 
vaccines, phage-based vaccines and 
recombinant vaccines produced in cell 
culture. Proteins produced using each of 
these systems have been approved by the 
FDA for use in humans.
Rapid production of DNA vaccines. 
The initial vaccine sequence designed in 
silico can be electronically provided to a 
production facility, where a cassette rep-
resenting the vaccine genetic construct(s) 
is then synthesized and inserted into a 
standardized DNA vaccine plasmid. A 
cGMP seed lot of bacteria containing 
the vaccine plasmid with cassetted pay-
load can be rapidly produced and vialed 
using existing SOPs for release and char-
acterization assays. An initial manufac-
turing lot of plasmid vaccine would be 
produced from the seed lot and used to 
initiate safety studies. To reduce time to 
produce sufficient vaccine product, mul-
tiple scale-up facilities could be located in 
different regions of the US. Using current 
methods of DNA vaccine development, 
seed lot production would take one to 
three weeks. Scale-up for DNA produc-
tion is much more rapid than traditional 
vaccine designs; only three to four weeks 
would be required to produce one million 
doses per facility. See below for discussion 
of Biological Agents Research Defense 
Agency (BARDA) appropriations for the 
construction of distributed vaccine pro-
duction facilities.
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foreground with lessons applicable to 
influenza T cell-driven vaccine devel-
opment. Perhaps the most prominent 
example of this new focus is the expand-
ing use of T cell-driven immunotherapy 
as an adjunct to cancer therapy. Many of 
the barriers to effective T cell-driven vac-
cine development are being addressed and 
surmounted in clinical cancer trials. For 
example, dendritic-cell pulsing vaccines 
using tumor antigens have moved into 
clinical use.40,41 Outcomes of these types 
of vaccination protocols have improved as 
MHC class II epitopes (CD4+ T cell help) 
were included42 and antibodies against 
cytotoxic T lymphocyte antigen-4 (anti-
CTLA-4; see ref. 43) and other anti-T 
regulatory cell (Treg) agents have been 
added to the conditioning regimen.
Quite a few T cell-driven vaccines 
are currently in human clinical trials 
(reviewed by Gilbert in 2012; see ref. 
44). While it is true that infectious dis-
ease T cell-driven vaccines have lagged 
behind T cell-driven vaccines for cancer, 
the regulatory pathway for T cell vaccines 
is improving, since more than 250 cancer 
vaccines that are based on T cell-driven 
immune responses are in clinical trials.a 
Furthermore, recent challenge studies 
have shown that humoral immunity is not 
required for protection against all human 
pathogens. This was demonstrated in the 
case of influenza, following vaccination of 
study participants with a multi-antigen 
vaccine. Following exposure to live influ-
enza virus, two of 11 vaccinees and five of 
11 control subjects developed laboratory-
confirmed influenza (symptoms plus virus 
shedding). Symptoms of influenza were 
less pronounced in the vaccinees and there 
was a significant reduction in the number 
of days of virus shedding in those vac-
cinees who developed influenza (mean 
of 1.09 d in controls, 0.45 d in vaccinees, 
p = 0.036)45,46 for a final efficacy of 60%, 
which is better than many vaccines cur-
rently available.
This is a major milestone for T cell vac-
cines for infectious disease, as it is one of 
the first vaccines to reach a Phase 2 clini-
cal trial and none have reached Phase 3. 
While one cannot directly extrapolate 
from this trial nor the many cancer T 
cell-driven immunotherapy trials to state 
that the approach will work for all types 
involve redundancy and higher costs, it 
would allow for the rapid production and 
scale-up of vaccines at any given moment. 
Each site would need to utilize the same 
manufacturing process to ensure consis-
tency across vaccine batches, and entities 
would need to be willing to share their 
specific methodologies to harmonize an 
approach. One site would create the mas-
ter cell bank (MCB), and then generate 
the manufacturer’s working cell bank 
(MWCB) for distribution to all other 
sites. In order to reduce production time 
by two weeks, this step would be per-
formed “at risk,” meaning MWCBs would 
be distributed prior to the completion of 
testing on either the MCB or MWCB. 
Sequencing on the MCB could likely be 
completed before the MWCB goes into 
fermenter starters. Assuming that a dose 
would constitute 0.2 mg of DNA vaccine 
and that each site has several 240 L fer-
menters (either as back-ups or for parallel 
growth), one million doses (200 g) per site 
could be produced in a three- to four-week 
period. BARDA recently invested hun-
dreds of millions of dollars in distributed 
influenza vaccine production; adapting 
these facilities for DNA vaccine produc-
tion would be an added but not insur-
mountable expense (as compared with the 
initial investment).39
An in vitro assay like the MIMIC sys-
tem could serve as a release characteristic 
of the multi-site lots that would run in 
parallel with the patch loading, preventing 
a single problematic DNA vaccine batch 
from impeding the release of patches gen-
erated with other batches. If the backbone-
host system is proven to be rugged with 
virtually any type of insert, a pilot run 
would no longer be necessary. Conversely, 
if the system is not shown to be rugged, 
then pilot runs would be important, as 
some inserts can greatly influence stabil-
ity and growth characteristics. Such pilot 
runs would need to be undertaken at 
every facility, most likely with different 
methods tested, to maximize the likeli-
hood of determining the best method for 
production.
Summary
A number of technological advances are 
moving T cell-driven vaccines to the 
influenza vaccine and will not rely on 
related, but different, vaccines already 
approved. Advance trials will establish 
correlates of protection for a FastVax 
influenza vaccine to serve as a basis for 
regulatory review in an emergency. In a 
pandemic, a novel FastVax sequence com-
position might be rapidly tested in a small, 
swiftly completed safety and immunoge-
nicity trial, much like EMA precedence 
for annual influenza vaccine updates.
Step four: Approval and emergency use 
authorization. One means of obtaining 
initial FDA review, experience and over-
sight for the FastVax vaccine-on-demand 
system would be to firmly establish the 
immunogenicity of an existing, clinical-
trial-ready DNA influenza virus vaccine 
in a patch or scarification delivery system. 
Demonstration that the vaccine candi-
date meets influenza correlates of protec-
tion criteria with an acceptable profile in 
human trials would inform regulatory 
review for products of similar composition, 
much as current regulatory policy supports 
annual marketing re-authorization despite 
changes in influenza subunit vaccine com-
position (from trivalent to quadrivalent) to 
reflect seasonal shifts and drifts.
Timely approval by the FDA to allow 
distribution of product in response to a 
rapidly emerging threat would require 
close cooperation between the vaccine 
manufacturer and the Agency. The man-
ufacturer can assist by providing clini-
cal safety and efficacy data for a variety 
of vaccine products based on standard-
ized vaccine platform, manufacturing, 
specifications, operating procedures and 
method of delivery. If the manufacturer 
can establish predictable immunogenic-
ity of epitopes in a demonstrated safe and 
reproducible vaccine platform and rapidly 
perform Phase I and Phase II trials estab-
lishing safety and immunogenicity in 
terms of a surrogate endpoint that predicts 
clinical benefit, the Agency may be able 
to provide a rapid review and emergency 
use allowance/authorization; release of the 
vaccine would then be possible through 
emergency use authorization by the HHS 
Secretary.
Scale up. To reduce the time to vaccine 
production, manufacturing sites could be 
pre-inspected and maintained at a state of 
operational readiness. While this would 
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Endnote
aThere are 276 clinical trials for “T cell 
vaccines” currently reported at http://
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